中文

Traphaco

₫35,050
+0.00% 2026-10-30 · Close
AI Composite Signal
6.9 / 10
Bullish — 5-signal composite
Mkt Cap
3.2T
₫3.2T
P/E
11.1
P/B
2.1
ROE
19.0%
ROA
12.4%
EPS
7.2K
Price Chart
What matters now

Traphaco (TRA) is a company in Vietnam's Health Care sector, listed on HOSE. The stock last traded at 35,050 VND, little changed on the session, giving a market capitalization of 3.2 trillion VND.

On valuation, TRA trades at a price-to-earnings ratio of 11.1 and a price-to-book of 2.1. That is a discount to the Health Care sector average P/E of 18.9. Return on equity of 19.0% points to solid profitability relative to the company's equity base, above the sector average of 11.3%. Trailing earnings per share stand at 7,211 VND.

Aveluro tracks 11 news items mentioning TRA, where recent coverage skews positive (54% of articles). The most recent catalyst was an earnings beat event — "Traphaco (TRA) 2025 Profit Up 8% as H1 2026 Earnings Surge 127%". Aveluro's composite model rates TRA 6.9/10 (Bullish), blending news sentiment, price momentum, and fundamentals.

Comparable names in the Health Care sector include AGP, AMP and AMV.

Latest catalyst

Traphaco (TRA) 2025 Profit Up 8% as H1 2026 Earnings Surge 127%

Recent Developments

Recent developments around Traphaco include 5 notable classified events. On Oct 10, 2026, an earnings beat was reported: Traphaco (TRA) closed 2025 with consolidated net revenue of VND 2,657 billion (+13%) and net profit of VND 278 billion (+8%), both above plan, then lifted H1 2026 net profit 127% year on year to VND 142.5 billion. On Oct 10, 2026, a market event was reported: Traphaco (HOSE: TRA) was fined VND 160 million by the Ministry of Health's Drug Administration for three manufacturing violations, including unapproved changes to registered drug files and improper use of talc in production. On Aug 13, 2026, a market event was reported: SCIC's 2026-2030 restructuring plan targets full divestment from 66 enterprises, potentially adding significant supply to the market, while retaining stakes in 21 firms including Vinamilk (VNM), Sabeco (SAB), and FPT. On Jul 31, 2026, an earnings beat was reported: POW reported Q2 2026 pre-tax profit of VND 4,152 billion, up 413% year-on-year, lifting H1 profit to VND 5,559 billion (+321%). On Jul 18, 2026, a dividend announcement was reported: CTG and VCB will each disburse over VND 3,000 billion in cash dividends at 4.5% rate, with ex-date July 23 and 24 respectively.

The overall tone of recent coverage is positive, with 3 of 5 events carrying bullish sentiment.

AI Signal Breakdown
Bearish Neutral Bullish
6.9 / 10
Bullish
Sentiment
+0.00
Impact
0.50
Momentum
-0.24
Fundamentals
+1.00
Volume
0.00
Sentiment 30% · Impact 20% · Momentum 20% · Fundamentals 15% · Volume 15%
News Sentiment
11
Articles Analyzed
Positive 6
Neutral 4
Negative 1
Recent News
Oct 10, 2026 Full Analysis Positive earnings beat
Traphaco (TRA) closed 2025 with consolidated net revenue of VND 2,657 billion (+13%) and net profit of VND 278 billion (+8%), both above plan, then lifted H1 2026 net profit 127% year on year to VND 142.5 billion. Management targets 2026 revenue of VND 2,923 billion and profit of VND 306 billion, funded by premium herbal and high-grade Western pharmaceutical lines plus EU-GMP plant investment.
Oct 10, 2026 Full Analysis Negative legal action
Traphaco (HOSE: TRA) was fined VND 160 million by the Ministry of Health's Drug Administration for three manufacturing violations, including unapproved changes to registered drug files and improper use of talc in production. Regulators applied maximum penalties after finding repeat and large-scale violations, adding to a pattern of tax-related penalties in 2018, 2023 and February 2026.
Aug 13, 2026 Full Analysis Neutral stake change
SCIC's 2026-2030 restructuring plan targets full divestment from 66 enterprises, potentially adding significant supply to the market, while retaining stakes in 21 firms including Vinamilk (VNM), Sabeco (SAB), and FPT. The list is flexible, so actual divestment pace will vary by company and market conditions.
Jul 31, 2026 Full Analysis Positive earnings beat
POW reported Q2 2026 pre-tax profit of VND 4,152 billion, up 413% year-on-year, lifting H1 profit to VND 5,559 billion (+321%). VNZ also surged 701% in Q2, while BCM and DXS posted sharp declines, highlighting divergent earnings across HOSE-listed sectors.
Jul 18, 2026 Full Analysis Positive dividend announcement
CTG and VCB will each disburse over VND 3,000 billion in cash dividends at 4.5% rate, with ex-date July 23 and 24 respectively. DBM pays the highest rate at 35%, benefiting major shareholder TRA.
May 13, 2026 Full Analysis Neutral sector sentiment
Vietnam's top three pharma companies by market cap—DHG, IMP, and DHT—are now under foreign control or significant influence, with Taisho, Livzon, and ASKA as key shareholders. The sector is projected to double from $8-9 billion to $16 billion by 2032, driving M&A interest.
Full Analysis Neutral m a announcement
IMP is now majority-owned by China's Livzon after a VND 6,000B deal for 67.87% of shares. The acquisition gives Livzon control of IMP's 12 EU-GMP production lines, a rare asset in Vietnam.
Related Stocks — Health Care
Stock Analysis

By Aveluro Research Team · Editorial policy · Caveat: Not investment advice. · How Aveluro computed this

Information provided for educational purposes only. Past performance does not guarantee future results. Data sourced from public Vietnamese market feeds.

Last updated: 2026-10-30T21:57:19Z.